Decitabine 化学構造
分子量: 228.21

高品質保証

カスタマーフィードバック(3)

MSDS

製品説明

  • Compare DNA Methyltransferase Inhibitors
    DNA Methyltransferase製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Decitabineは一種のDNA methylationの有効な阻害剤で、骨髄異形成症候群(MDS)を治療することに使用されます。
ターゲット DNA methyltransferase (HL-60) DNA methyltransferase (KG1a)
IC50 100 ng/mL 1 ng/mL [1]
In vitro試験 Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
Eca109 MXHGeY5kfGmxbjDBd5NigQ>? NGS4ZlYxNjYEoN88US=> MlexNlQhcA>? M37MOJdifGW{ NFrXZmdud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? MUGyOVEzOzB6Mh?=
Eca109 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonvNE42NzJwNT:1JO69VQ>? M3;SNlI1NzR6L{eyJIg> NIf1T5J4[XSnch?= NIPIfo5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MnvyNlUyOjNyOEK=
Eca109 MUfGeY5kfGmxbjDBd5NigQ>? Ml3oNE42yqEQvF2= MnfxOk8yOi9{NDDo M1T5TJdifGW{ MonEbY5pcWKrdIOgZ4VtdCCvaXfyZZRqd28EoB?= MnHBNlUyOjNyOEK=
Eca109 NIDZdnVHfW6ldHnvckBCe3OjeR?= NFfFfJExNjYEoN88US=> M3nHdlI1KGh? MnLae4F1\XJ? NWj3VGxKcW6qaXLpeJMh[2WubDDpcpZie2mxbh?= NW\MPXVGOjVzMkOwPFI>
Eca109 MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XYPFAvPcLizszN MU[yOEBp MlHve4F1\XJ? NG\U[oZqdmS3Y3XzJGczN01iYYLy[ZN1KGmwIITo[UBk\WyuIHP5Z4xm NUfIPWRHOjVzMkOwPFI>
Eca109 NXTlW|ZlTnWwY4Tpc44hSXO|YYm= NXf0Rm5[OC53L{Gg{txO MUKyOEBp MkPpe4F1\XJ? M3XnXoRm[3KnYYPld{BmgHC{ZYPzbY9vKG:oIF7GMe67SjJiYX7kJG1OWDJ? NI\nNpUzPTF{M{C4Ni=>
SW1116  MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:wMlUwOS9{L{Wg{txO NXLOSGN[PDhiaB?= NFnkbIdFVVOR MorW[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> MlnKNlQ5PzR{OE[=
LOVO MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\PWZhWOC53L{GvNk82KM7:TR?= MVK0PEBp MmTxSG1UVw>? NYD1VmRS\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? MUSyOFg4PDJ6Nh?=
SW1116  NXnFWllLTnWwY4Tpc44hSXO|YYm= MXOxNEDPxE1? MXW0PEBp MWTEUXNQ NXzFdohJcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk M4H0dFI1QDd2Mki2
LOVO MnvXSpVv[3Srb36gRZN{[Xl? MUixNEDPxE1? NH33W|Y1QCCq M3PucWROW09? MXHpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> NGO2NWMzPDh5NEK4Oi=>
SW1116  MVTBdI9xfG:|aYOgRZN{[Xl? NHPJb2kyOCEQvF2= NXv4UnJ1PDhiaB?= NWfvXZN6TE2VTx?= M3nxNoVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> M3zRO|I1QDd2Mki2
LOVO MWfBdI9xfG:|aYOgRZN{[Xl? M3XCflExKM7:TR?= MlnBOFghcA>? MlHZSG1UVw>? MVXlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= NGrDOnkzPDh5NEK4Oi=>
RPMI-8226 NGmxcHpCeG:ydH;zbZMhSXO|YYm= NHrxUpUyNzJizszN MkPaOFgwPzJxOU[gbC=> MWfEUXNQ NIL5Um5qdmS3Y3XzJINmdGxiYYDvdJRwe2m| M3rDS|I1QDN|MUC4
OPM-2  NF;1WG9CeG:ydH;zbZMhSXO|YYm= NUXvc3pGOS9{IN88US=> M1LDSlczNzl4L{GyNEBp MkfrSG1UVw>? M1\YWIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M2riZVI1QDN|MUC4
JJN3  NYK5VmhrSXCxcITvd4l{KEG|c3H5 M{jjVVAvPS9zIN88US=> NUDrVGZnOjRxNEigbC=> NHv3TW1FVVOR Mn;UbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? Mkj5NlQ5OzNzMEi=
NCI-H929  M1L5WWFxd3C2b4Ppd{BCe3OjeR?= MlniNU8zKM7:TR?= MYi3Nk86Pi9zMkCgbC=> Mmn1SG1UVw>? NFe2[|VqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NULJR5c6OjR6M{OxNFg>
RPMI-8226 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:xM|Ih|ryP MX6yOE81QC95MjDo M{HSNGROW09? Ml7uZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? M{nmVlI1QDN|MUC4
OPM-2  Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TMWlEwOiEQvF2= NY\YcI5yOjRxNEivO|IhcA>? MmPDSG1UVw>? NXfybI5z[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NYPuc5BvOjR6M{OxNFg>
JJN3  NEfvb3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqwMlUwOSEQvF2= M3H1ZlI1NzR6L{eyJIg> Mlr4SG1UVw>? NYezPXNV[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NGCxclQzPDh|M{GwPC=>
NCI-H929  NIHGc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTvfHRvOS9{IN88US=> NEP6[2QzPC92OD:3NkBp MYLEUXNQ NF\OWWli\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MVGyOFg{OzFyOB?=
HeLa M2fxTmtqdmG|ZTDBd5NigQ>? MUPLbV0yODBy4pETOVAxOCEQvF2g[o9zKGiHTmSx M1LoUFI1PzhyMEm4
HeLa M1\rNGtqdmG|ZTDBd5NigQ>? NV;lRXNOU2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz MXSyOFc5ODB7OB?=
HeLa NVLBNpBpU2mwYYPlJGF{e2G7 NX\mbFZGU2l;MkGuOkDDuSB|LkCg{txOKG[xcjDoR25VOQ>? NX72eJpUOjR5OECwPVg>
HeLa M1PIbWtqdmG|ZTDBd5NigQ>? MV\LbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz NIP5UnMzPDd6MEC5PC=>
NB4 Mli1SpVv[3Srb36gRZN{[Xl? M3\IdVIvPS93L{euOU8yOCEQvF2= MkLMNlQhcA>? Ml2xSG1UVw>? M4rROIlv[3KnYYPlZUB1cGViZYjwdoV{e2mxbjDv[kBxemWldYLzc5IhdWmULUGyOYE> NUTHWJJXOjR2OES4O|A>
CD4+ CD25− T  MWPGeY5kfGmxbjDBd5NigQ>? NEnZVncyNzVizszN MXfy[YR2[2WVIHfsc4JidCCGTlGgcYV1cHmuYYTpc44> NIDFTngzPDR5NkO2NC=>
BV-173 M4HPNmFxd3C2b4Ppd{BCe3OjeR?= NGHyRWkxNjJ3L{CuOU8xNjd3L{Gg{txO NVfRSJlGPDhxN{KvPVYhcA>? M3fvfeKhWEKV NX\DeGZtcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MnvnNlQ1OjN4MUO=
ML-1 NHrWSI5CeG:ydH;zbZMhSXO|YYm= M4XUZ|AvOjVxMD61M|AvPzVxMTFOwG0> NXfPbotRPDhxN{KvPVYhcA>? Ml7SxsBRSlN? MmLabY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NVv4SVh7OjR2MkO2NVM>
HL-60 M1nZUWFxd3C2b4Ppd{BCe3OjeR?= NG\xPJMxNjJ3L{CuOU8xNjd3L{Gg{txO M13IZ|Q5Nzd{L{m2JIg> MnHoxsBRSlN? NXnCV3NVcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MkLENlQ1OjN4MUO=
KG-1a NX3R[281SXCxcITvd4l{KEG|c3H5 NXjiNXdTOC5{NT:wMlUwOC55NT:xJO69VQ>? MoLWOFgwPzJxOU[gbC=> M1vTVeKhWEKV MX7pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NEHxe|UzPDR{M{[xNy=>
BV-173 MonoSpVv[3Srb36gRZN{[Xl? MYiyOVAwPTBybl2= M2P2flQ5KGh? MYVCpHBDWw>? M{\vTolv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MXyyOFQzOzZzMx?=
CEM NETpfINHfW6ldHnvckBCe3OjeR?= NUDH[pAyOjVyL{WwNI5O MY[0PEBp MXtCpHBDWw>? NV7rNoZWcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NGDvUo8zPDR{M{[xNy=>
HL-60 MVjGeY5kfGmxbjDBd5NigQ>? NEP1fIgzPTBxNUCwcm0> M4LzclQ5KGh? MWpCpHBDWw>? NUP1dlJWcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NXLLSmh7OjR2MkO2NVM>
ML-1 MYHGeY5kfGmxbjDBd5NigQ>? MXqyOVAwPTBybl2= MlPsOFghcA>? Ml7JxsBRSlN? M4XMNYlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NGTiV28zPDR{M{[xNy=>
DLD-1 M4j2d2Z2dmO2aX;uJGF{e2G7 M2\vUlI2OC93MEDuUS=> NIn6b4E1QCCq M4\6R:KhWEKV MoPU[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? MmnuNlQ1OjN4MUO=
HCT-116 NWWydllRTnWwY4Tpc44hSXO|YYm= MnXENlUxNzVyMH7N M2rPVlQ5KGh? MWNCpHBDWw>? M3;DbIRwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? M1nzc|I1PDJ|NkGz
U937-A/E-9/14/18  NXvmZYhsSXCxcITvd4l{KEG|c3H5 MkHnNE4xOS9yLkGvNU8yOCEQvF2= NXLKXGVDPDhiaB?= NUjCdZVxcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3OxRVI1OzByNEW2
HT29 NV;Y[4gyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnjS2NVPzJiaB?= MnrXTWM2OD1zNECwxtEyPzlizszN M4[yXlI1OTd{ME[x
SW48 NFWwRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXuwcZRQPzJiaB?= NHPG[5FKSzVyPUG1MlLDuTZwMjFOwG0> MXGyOFE4OjB4MR?=
HCT116 NF\D[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH2fJlKPzJiaB?= NHTBTWlKSzVyPUGuO:KyOC52IN88US=> NGfzWXkzPDF5MkC2NS=>
HepG2 MX3GeY5kfGmxbjDBd5NigQ>? MmTyNE42NzFizszN MofVNlQhcA>? MX\EUXNQ Mlm5eZAuemWpdXzheIVlKHSqZTDy[YxifGm4ZTDPR3RPOiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NEHTTGwzPDF2Nki3OC=>
LS174T NUnMZ5J4TnWwY4Tpc44hSXO|YYm= NHnLZYkxNjVxMTFOwG0> NF7QcpMzPCCq MlrKSG1UVw>? NWDIdVhCdGWjZDD0c{BidiCrbnPy[YF{\SCxZjDPR3RPOiCuZY\lcJM> NHXNcoozPDF2Nki3OC=>
HepG2 NWPKW2R1SXCxcITvd4l{KEG|c3H5 MlXSNU8yOC9zMECg{txO MV63JIQ> MX3EUXNQ M3rEdolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1zrNFI1OTR4OEe0
LS174T NWHjbWRzSXCxcITvd4l{KEG|c3H5 NXzBV4JlOS9zMD:xNFAh|ryP MofNO{Bl Mn:zSG1UVw>? M{jOT4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUTxSFgxOjRzNE[4O|Q>
QBC-939 M3PaeWFxd3C2b4Ppd{BCe3OjeR?= NVnWfW05OS9zMD:xNFAh|ryP NFPNdog4KGR? NGHGS|dFVVOR NV[5R21qcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYqyOFE1Pjh5NB?=
U251 NGXINnpCeG:ydH;zbZMhSXO|YYm= MYWxM|ExNzFyMDFOwG0> MVi3JIQ> MnPRSG1UVw>? M3jWXolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXTlS3FxOjRzNE[4O|Q>
HL-60 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW3e4MyKM7:TR?= NEC5[FY1QCCq MVHpcoNz\WG|ZYOgS|IueGijc3WgZ4VtdCCocnHjeIlwdg>? NIDlNZgzPDByMEOyOC=>
MDA‑MB‑453 NVqxSnhFTnWwY4Tpc44hSXO|YYm= MofrNE4zNzFizszN NHu0OnM4OiCq NILpfFdk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> NXTNSlZSOjN6NESyNlg>
HCC1569 MVzGeY5kfGmxbjDBd5NigQ>? NH\PVHgxNjJxMTFOwG0> NHnETVE4OiCq MXnjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= M2P1[VI{QDR2MkK4
BT‑474 MX;GeY5kfGmxbjDBd5NigQ>? M1W5eVAvOi9zIN88US=> NW\WXIc5PzJiaB?= MVHjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= NFzxS5EzOzh2NEKyPC=>
AGS NIXBXnhCeG:ydH;zbZMhSXO|YYm= MVO1M|ExNzJyL{WwJO69VQ>? M{CwbVQ5yqCqwrC= M{H4c2ROW09? NIHCeHdqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? NF3KSVczOzV6Mke4OC=>
A549 MVzBdI9xfG:|aYOgRZN{[Xl? MXS1M|ExNzJyL{WwJO69VQ>? NGjlPJQ1QMLiaNMg MYjEUXNQ NF7TOZdqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? NWPpRYYyOjN3OEK3PFQ>
AGS  NHnwWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G3VlUwOTBxMkCvOVAh|ryP NIXBOnY1QMLiaNMg NGeyXlJFVVOR MVTpcoR2[2W|IFeyM20heGijc3WgZZJz\XO2wrC= NELIWWwzOzV6Mke4OC=>
Kasumi-1 M4fYOWFxd3C2b4Ppd{BCe3OjeR?= MYKwMlUh|ryP MkHqOFjDqGkEoB?= MXrk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= NUj5SGd[OjN2OUOzOFg>
OCI-AML3 NF[3e4tCeG:ydH;zbZMhSXO|YYm= NGnr[IczNjVizszN NGL6cZA1QMLiaNMg M{PaToRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj MYqyN|Q6OzN2OB?=
MV4-11 MUPBdI9xfG:|aYOgRZN{[Xl? NHH5T|YzNjVizszN NVPrOYtTPDkEoHlCpC=> MUPk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= NV;od5VtOjN2OUOzOFg>
NK  NUfWWFluS3m2b4TvfIl1gSCDc4PhfS=> MX:wMlAzNTJyIN88US=> NGnkO|M2KGR? NWDaS|lG\GWlcnXhd4V{KHSqZTDjfZRwdHm2aXOgZYN1cX[rdImgc4YhVktiY3XscJMh[XRiaX70[ZJu\WSrYYTlJINwdmOnboTyZZRqd26|IILld5VtfGmwZzDpckBiKFVvc3jhdIVlKGSxc3ZihLNz\XOyb37z[UBkfXK4ZR?= MVWyN|MzQDB6OB?=
NK  MojxRZBweHSxc3nzJGF{e2G7 NVKzdZdROC5yMj2yNEDPxE1? NX;jXJB7PSCm NFT5TmNl\WO{ZXHz[UBPUyClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fUBieyC2aHWgZ49v[2WwdILheIlwdiCrbnPy[YF{\WR? NH;QbFkzOzN{OEC4PC=>
NK  M4DJNmZ2dmO2aX;uJGF{e2G7 NYnWOnA1OC5yMT2yNEDPxE1? Mny2OUBl Mn7YZ4F2e2W|IHj5dI9u\XSqeXzheIlwdiCxZjDOT{Bk\WyuczDpckBiKGSxc3ZihLNz\XOyb37z[S=> NXnafnNXOjN|MkiwPFg>
MOLT4/DNR M3XaXWZ2dmO2aX;uJGF{e2G7 NE[zVFE2KM7:TR?= MUC0JIQ> MV\y[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> NX:wdG83OjNyNkC1O|A>
Jurkat/DOX M{DnRmZ2dmO2aX;uJGF{e2G7 MUO1JO69VQ>? M33aNlQh\A>? NG\nTVRz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? M3zNfVI{ODZyNUew
MOLT4/DNR MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXpd202KM7:TR?= NUTnUVFQPCCm MXTy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 NVXrfpNiOjNyNkC1O|A>
Jurkat/DOX NWLNcHE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfT[WU2KM7:TR?= MV:0JIQ> NIrDfWZz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 NGiwNnUzOzB4MEW3NC=>
ccRCC  M1i2bWFxd3C2b4Ppd{BCe3OjeR?= M1PWZVAvODFvMUFOwG0> M2fjN|czKGh? NHiwUGFFVVOR NXfuOZhscGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= MXyyNlgzPjR4Nx?=
TNBC  MlXYRZBweHSxc3nzJGF{e2G7 MnfzNE4xOS1zMN88US=> MlvrO|IhcA>? MYTEUXNQ Mn3kbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? MlOxNlI5OjZ2Nke=
A498 M2r5XmFxd3C2b4Ppd{BCe3OjeR?= NH;wXJAxNjBzLUGw{txO NGjzWmc4OiCq NX21dVZ2TE2VTx?= NWDsXVNlcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NWizTXR7OjJ6Mk[0Olc>
KIJ265T NVXzWoYySXCxcITvd4l{KEG|c3H5 M{naPVAvODFvMUFOwG0> NF30cHQ4OiCq MWjEUXNQ MlfsbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MWSyNlgzPjR4Nx?=
MDA-231 M2\FNGFxd3C2b4Ppd{BCe3OjeR?= M2\4ZlAvODFvMUFOwG0> NXXZR5lXPzJiaB?= M2TSUWROW09? M{PqUYlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> Ml\ONlI5OjZ2Nke=
BT-20 NFLBcpVCeG:ydH;zbZMhSXO|YYm= Mn2xNE4xOS1zMN88US=> NXKzNpNnPzJiaB?= MX;EUXNQ MoHYbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MlPqNlI5OjZ2Nke=
U937 NXP3fmVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O3WlUuOjBizszN NYjQRo86OjRxNEivO|IhcA>? NWe0SHE2cW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M3e5dlIzPzZ5MEKx
HL60 NFjuZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTmNm9VPS1{MDFOwG0> MnnNNlQwPDhxN{KgbC=> M3\yV4lv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MmW1NlI4PjdyMkG=
U937 NFvLS4ZCeG:ydH;zbZMhSXO|YYm= M2nFeVE2KM7:TR?= MojRNlQwPDhxN{KgbC=> MnPlbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MlTqNlI4PjdyMkG=
HL60 M2e5bWFxd3C2b4Ppd{BCe3OjeR?= MnTxNVUh|ryP NXjPRpR{OjRxNEivO|IhcA>? M1vlPIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NYLxOZY3OjJ5NkewNlE>
LS411N  NUTncIRbSXCxcITvd4l{KEG|c3H5 NITwRnIxNjVizszN MoPPO|IhcA>? MmXGbY5kemWjc3XzJGZieyCvUl7BJIxmfmWu MX2yNlQ3OTZ7NR?=
MDA-MB-231 MX\BdI9xfG:|aYOgRZN{[Xl? MoDuNVAh|ryP NHfIcpc1QCCq NE\ZXYdz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVqyNVg5PzZ7Nx?=
MCF-7  MYLBdI9xfG:|aYOgRZN{[Xl? MVyxNEDPxE1? MoDGOFghcA>? NX:0T5hUemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoXsNlE5QDd4OUe=
A375 MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrrRoJ3OC53IN88US=> M4H6WlEwPS96IHS= NVLORmRscW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MUOyNVc6PjZ{Mh?=
SKMEL1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPO[JoxNjVizszN MXixM|UwQCCm NYLiW49rcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NX\WOVJqOjF5OU[2NlI>
SKMEL3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\rNE42KM7:TR?= NWnpS|FbOS93L{ig[C=> NXXmSHFzcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MmDDNlE4QTZ4MkK=
SKMEL28 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrCNE42KM7:TR?= MYGxM|UwQCCm NIfrWI1qdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NXjvRpRHOjF5OU[2NlI>
MeWo MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSwMlUh|ryP M1HB[|EwPS96IHS= NVS3eYlOcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MUSyNVc6PjZ{Mh?=
B16 Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\PNFAvPSEQvF2= MojoNU82NzhiZB?= NXnpOG1DcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MmC5NlE4QTZ4MkK=
Ly 1 M2fze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XEOVI1KGh? MUTJR|UxRTdwMzFOwG0> NWmzdm1uOjF5N{KwOFk>
Ly 7 MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETORXczPCCq MmDUTWM2OD1zMD63JO69VQ>? MXqyNVc4OjB2OR?=
Su-DHL6 NETMb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPuVHNmOjRiaB?= MlLXTWM2OO,:nkKwJO69VQ>? NUXJXY81OjF5N{KwOFk>
Ly 10 NYKzOWxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXMOYoyOjRiaB?= MYHJR|Ux97zgMkCg{txO MX6yNVc4OjB2OR?=
RIVA MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqyOEBp M3\w[mlEPTExvK6yNEDPxE1? MlXnNlE4PzJyNEm=
Su-DHL2 M{XqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWeyOEBp M2D2PWlEPTExvK6yNEDPxE1? NEP6XmEzOTd5MkC0PS=>
Ly 1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfFOFghcA>? NFrjcYVKSzVyPUCuN|Qh|ryP NVjkWJd3OjF5N{KwOFk>
Ly 7 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHpWIc1QCCq NHTFc4tKSzVyPUCuNFI2KM7:TR?= NFeydHAzOTd5MkC0PS=>
Su-DHL6 MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYm0PEBp MWPJR|Ux97zgMkCg{txO M3f3fVIyPzd{MES5
Ly 10 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\rSVQ5KGh? NVXwOFV7UUN3ME2xMlgh|ryP MXqyNVc4OjB2OR?=
RIVA NHXJbWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYG0PEBp MUjJR|Ux97zgMkCg{txO NV33e2ZvOjF5N{KwOFk>
Su-DHL2 NXLtXmRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXq0PEBp NVLUcpI2UUN3ME2xO{41KM7:TR?= MoPXNlE4PzJyNEm=
Ly 1 M1nSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnWRlU4OiCq NGDDb4RKSzVyPUCuNFEh|ryP M1jPWVIyPzd{MES5
Ly 7 M3;VO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjlVnA4OiCq MWfJR|UxRTBwMEG4JO69VQ>? NX[xSHp3OjF5N{KwOFk>
Su-DHL6 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[3NkBp MUDJR|UxRTFwNjFOwG0> M3LMblIyPzd{MES5
Ly 10 NHi5R5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHNcYg4OiCq M{joZWlEPTB;MT6yJO69VQ>? MWSyNVc4OjB2OR?=
RIVA NH3n[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnJUWk4OiCq MYnJR|Ux97zgMkCg{txO NH;2e4YzOTd5MkC0PS=>
Su-DHL2 NFzw[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\xSlczKGh? NFLSW2JKSzVyPUGxMlIh|ryP NHv2ZVYzOTd5MkC0PS=>

... Click to View More Cell Line Experimental Data

In vivo試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]
臨床試験 Decitabine is currently in Phase I clinical trials in patients with Higher-risk MDS and MDS/AML Receiving Allogeneic Stem Cell Transplantation.
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

DNA synthesis assay The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.

細胞アッセイ: [1]

細胞株 HL-60 and KG1a
濃度 0-500 nM
反応時間 96 hours
実験の流れ For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.

動物実験: [2]

動物モデル KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
製剤 Decitabine is dissolved in sterile PBS .
投薬量 ≤2.5 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Decitabine SDF
分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管 3年-20℃
2年-80℃in solvent
別名 Deoxycytidine
溶解度 (25°C) * In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one

文献中の引用 (6)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related DNAメチルトランスフェラーゼ 阻害剤

最近チェックしたアイテム

Tags: Decitabineを買う | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ